ArticleHeart and vessels2026
Impact of short membranous septal length on overall survival after transcatheter aortic valve replacement.
Article in Heart and vessels, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Transcatheter aortic valve replacement (TAVR) is an established therapy for severe aortic stenosis, although conduction disturbances, especially atrioventricular block and new-onset left bundle branch block (LBBB) remain associated with adverse outcomes. Short membranous septal length (MSL) has been linked to post-TAVR conduction abnormalities, but its prognostic significance is unclear. We retrospectively analyzed 258 patients who underwent transfemoral TAVR. MSL was measured on contrast-enhanced CT, and left ventricular ejection fraction (LVEF) was assessed at baseline, 1 week, and 1 year. The primary endpoint was all-cause mortality; secondary was a composite of mortality or heart failure hospitalization. Patients were classified by MSL ≤ 6 mm or > 6 mm. The short MSL group had higher rates of new-onset LBBB (p = 0.047), mortality (p = 0.046), and the composite endpoint (p = 0.039). MSL ≤ 6 mm independently predicted mortality (HR 3.66, 95% CI 1.52-16.2, p = 0.0012) and the composite outcome (HR 2.56, 95% CI 1.32-6.69, p = 0.0025). LVEF recovery at 1 year was significantly impaired (p = 0.035), and these findings persisted after excluding patients with LBBB or pacemaker implantation. Incorporating MSL ≤ 6 mm into a model with established risk factors improved discrimination for mortality (AUC 0.72 vs 0.67, p = 0.042; cfNRI 0.33). Short MSL was associated with impaired LVEF recovery and adverse outcomes after TAVR. MSL may serve as a simple CT-based marker for preprocedural risk stratification.
Indexed as
Identifiers
41735656What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.